.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AE03_Ritonavir.Ritonavir .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AE03_Ritonavir.Ritonavir| name: | Ritonavir | |
| ATC code: | J05AE03 | route: | oral |
| compartments: | 2 | |
| dosage: | 600 | mg |
| volume of distribution: | 88.2 | L |
| clearance: | 14.7 | L/h |
| other parameters in model implementation | ||
Ritonavir is an antiretroviral medication belonging to the class of protease inhibitors. It is primarily used as a pharmacokinetic enhancer or booster of other protease inhibitors or direct-acting antivirals in the treatment of HIV/AIDS. Ritonavir is approved and widely used today in combination therapies as part of highly active antiretroviral therapy (HAART), as well as in combination with other antivirals for COVID-19.
Pharmacokinetic parameters for healthy adult volunteers following single oral dose administration.
Hammond, J, et al., & Rusnak, JM (2022). Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. The New England journal of medicine 386(15) 1397–1408. DOI:10.1056/NEJMoa2118542 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35172054
Chupradit, S, et al., & Musiime, V (2024). Population Pharmacokinetics of Pediatric Lopinavir/Ritonavir Oral Pellets in Children Living with HIV in Africa. Clinical pharmacology and therapeutics 115(5) 1105–1113. DOI:10.1002/cpt.3174 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38247190
Dickinson, L, et al., & Boffito, M (2020). Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. The Journal of antimicrobial chemotherapy 75(3) 628–639. DOI:10.1093/jac/dkz479 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31754703